Fast Track Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 29-12-2024
- Paid Up Capital ₹ 0.10 M
as on 29-12-2024
- Company Age 24 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -8.07%
(FY 2022)
- Profit -33.84%
(FY 2022)
- Ebitda -27.24%
(FY 2022)
- Net Worth 13.74%
(FY 2022)
- Total Assets 17.10%
(FY 2022)
About Fast Track Pharmaceuticals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pooja Khanna and Ravi Jaiswal serve as directors at the Company.
- CIN/LLPIN
U24230MH2000PTC129151
- Company No.
129151
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Oct 2000
- Date of AGM
26 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Fast Track Pharmaceuticals Private Limited offer?
Fast Track Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Capsules, Herbal Capsules, Liver Supplement, Ayurvedic Liver Tonic.
Who are the key members and board of directors at Fast Track Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Jaiswal  | Director | 01-Jul-2014 | Current |
| Pooja Khanna | Director | 25-Feb-2012 | Current |
Financial Performance of Fast Track Pharmaceuticals.
Fast Track Pharmaceuticals Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 8.07% decrease. The company also saw a substantial fall in profitability, with a 33.84% decrease in profit. The company's net worth Soared by an impressive increase of 13.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fast Track Pharmaceuticals?
In 2022, Fast Track Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Fast Track Pharmaceuticals?
Unlock and access historical data on people associated with Fast Track Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fast Track Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fast Track Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
